- Results of TBS-2 Phase II Vibrotactile Stimulation study yield positive outcomes for all Anorgasmia parameters
- Company to initiate multinational TBS-2 Phase II Ambulatory clinical program
- Dialogue with the United States Food and Drug Administration together with qualitative patient research has produced refined selection criteria and efficacy metrics for TBS-2 Phase II Ambulatory study
- Tefina™ filed with United States Patent and Trademark Office as TBS-2 trade name
[Read the rest of this article...]